We present a major public resource of mRNA splicing mutations validated according to multiple lines of evidence of abnormal gene expression. Likely mutations present in all tumor types reported in the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) were identified based on the comparative strengths of splice sites in tumor versus normal genomes, and then validated by respectively comparing counts of splice junction spanning and abundance of transcript reads in RNA-Seq data from matched tissues and tumors lacking these mutations. The comprehensive resource features 341,486 of these validated mutations, the majority of which (69.9%) are not present in the Single Nucleotide Polymorphism Database (dbSNP 150). There are 131,347 unique mutations which weaken or abolish natural splice sites, and 222,071 mutations which strengthen cryptic splice sites (11,932 affect both simultaneously). 28,812 novel or rare flagged variants (with <1% population frequency in dbSNP) were observed in multiple tumor tissue types. Single variants or chromosome ranges can be queried using a Global Alliance for Genomics and Health (GA4GH)-compliant, web-based Beacon "Validated Splicing Mutations" either separately or in aggregate alongside other Beacons through the public , as well as through our Beacon Network . website : Conceptualization, Funding Acquisition, Project Administration, Supervision, Validation, Writing -Original Draft Rogan PK Preparation, Writing -Review & Editing PKR cofounded and BCS is an employee of CytoGnomix Inc., which hosts the interactive webpage described in this study.
Amendments from Version 1
We updated Dataset 1 and the accompanying web resource, along with variant counts and statistics in the manuscript:
• We re-examined insertions and deletions (indels) with the new version of the Shannon pipeline (SP). Major updates to this version of SP include:
o Binding sites adjacent to indels are now correctly localized.
o Cryptic splice acceptor sites in the first exon and cryptic donor sites in the last exon of a gene are no longer reported.
o Information models derived from splicing regulatory and transcription factor binding sites can now be utilized.
• Genomic and transcriptomic data from the International Cancer Genome Consortium (ICGC) became available to us in January 2019. This dataset was evaluated using the same methods as those used for TCGA.
• Differences in the expression of predicted mutant splice forms between two distinct BAM files were discovered from the same tumour of the same patient. We reanalyzed and replaced results for all variants in the TCGA-ESCA dataset using a second set of RNAseq BAM files.
DNAStack is acknowledged by including a citation of their recent article describing beacons.
We discuss:
• Comparison of results obtained from the TCGA and ICGC datasets. Figure 2 summarizes this.
• Comparison of gene expression values in patients with mutations validated by Veridical vs predicted mutations in the same gene that did not achieve statistical significance using this algorithm.
• Comparison of Veridical-flagged, cryptic splicing mutations with results of another study which evaluated cryptic splicing in TCGA (Jayasinghe et al., 2018).
• Evaluation of a large set of validated splicing mutations (n=1050, Cheung et al., 2019).
The analyses reported in this paper are being adopted by the genomics community. Since the version 1 publication (07 Dec 2018), the internet resource described has been queried by the global Beacon Network 6906 times and through the ValidSpliceMut website 8523 times.
See referee reports

REVISED
due to ambiguous variant interpretation. Of the 458,899 variant submissions in NCBI's ClinVar database with clinical interpretations, nearly half (n=221,271) are VUS (as of November 5th 2018). Only 10,784 variants in ClinVar have been documented to affect mRNA splicing at splice donor or acceptor sites, with 1,063 of these being classified as VUS, and cryptic mRNA splicing mutations are not explicitly described. The current ACMG criteria 2 for variant pathogenicity prevent clinical classification of most VUS. Functional evidence that VUS either disrupt or abolish expression of genes has been sought to improve classification and provide insight into the roles, if any, of individual VUS in predisposing or causing disease. We present a comprehensive data repository for a relatively common mutation type (cis-acting variants that alter mRNA splicing). Mutations are predicted with information theory-based analyses 3 , and supported with functional evidence that variants in tumor genomes are specifically associated with abnormally spliced mRNAs that are infrequent or absent in transciptomes lacking these variants 4 .
Information theory (IT) has been proven to accurately predict impact of mutations on mRNA splicing, and has been used to interpret coding and non-coding mutations that alter mRNA splicing in both common and rare diseases 3,5-15 . We have described an IT-based framework for the interpretation and prioritization of non-coding variants of uncertain significance, which has been validated in multiple studies involving novel variants in patients with history or predisposition to heritable breast and/or ovarian cancer [11] [12] [13] [14] [15] . The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas (PCA) is a comprehensive integrated genomic and transcriptomic resource containing data from >10,000 tumors across 33 different tumor types 16 . Here, we utilized IT-based tools for assessment of high quality sequenced variants in TCGA patients, as well as patients from tumor datasets provided by the International Cancer Genome Consortium (chronic lymphocytic leukemia, esophageal adenocarcinoma, malignant lymphoma, pancreatic cancer endocrine neoplasms, as well as liver, ovarian, and renal cell cancers), for their potential impact on mRNA splicing. The accuracy of predicted mutations was evaluated with the algorithm we previously developed 4 that compares transcripts from individuals carrying these variants with others lacking them. The results of these genome-wide analyses are presented using an online internet resource, ValidSpliceMut, which can also be queried through the Beacon Network 17, 18 .
Methods
TCGA and ICGC data acquisition and processing
Controlled-access data was obtained with permission from the Data Access Committee at NIH for TCGA and from the International Cancer Genomics Consortium. Patient RNA sequencing BAM files (tumor and normal, when available) and their associated VCF files (GRCh37) were initially obtained from the CancerGenomeHub (CGhub). Files were later downloaded through Genomic Data Commons using the GDC Data Transfer Tool (version 1.3.0), as CGhub was decommissioned
Introduction
Next generation sequencing continues to reveal large numbers of novel variants whose impact cannot be interpreted from curated variant databases, or through reviews of peer-reviewed biomedical literature 1 . This has created a largely unmet need for unequivocal sources of information regarding the molecular phenotypes and potential pathology of variants of unknown significance (VUS); in cancer genomes, such sources are critically needed to assist in distinguishing driver mutations from overwhelming numbers of bystander mutations. VUS classification criteria highlight the limitations in genome interpretation mid-project. Genomic data from ICGC was downloaded through the Score client (version 1.5.0). Variants in VCF files which did not pass quality control (QC) were not analyzed.
Information analysis and RNA-Seq validation of splicing variants
We used the Shannon Pipeline software (SP; which applies IT to rapidly perform high-throughput, in silico prediction of the impacts of variants on mRNA splicing) 19 to analyze all QCpassing variants in VCFs from TCGA and ICGC (>168 million TCGA and >41 million ICGC variants) to evaluate their potential impact on splice site binding strength (changes in information content, R i , measured in bits). Variants which were predicted to strengthen known natural sites or weaken cryptic splice sites were excluded from all subsequent analyses. We also required novel cryptic splice sites to be strengthened by ≥ 2 bits (at least 4 fold), and with final strengths (R i,final ) exceeding that of the nearest natural site of the same polarity.
To validate the potential impact of SP-flagged mutations, Veridical software analyzed genomic variants (including insertions and deletions) by comparing the RNASeq alignment in the region surrounding the variant with the corresponding interval in control transcriptomes (normal and tumor tissue of the same type) lacking the variant 4, 20 . The Veridical algorithm: a) counts abnormally spliced reads in RNA-Seq data (categorized as either cryptic site use, exon skipping, or intron inclusion [containing or adjacent to the flagged mutation]), b) applies the Yeo-Johnson transformation to these results, and c) determines the null hypothesis probability (p-value) that the transformed read count corresponds to normal splicing. In tumor types where normal controls were not available, a set of RNA-Seq datasets from 100 different normal tissues from TCGA were used (e.g. a combination of 5 tissue types: BRCA, BLCA, LUAD, KIRC, PRAD). Veridical results that were not significant for a particular variant (p-value > 0.05 for all evidence types, or evidence of altered splicing consisting of fewer than 2 reads) were not further analyzed. After this analysis, Veridical validated 341,486 unique mutations for their direct impact on mRNA splicing (Table 1 ). The Shannon pipeline-flagged and Veridical-filtered results were combined into a single large table (Dataset 1 21 ) that contains the source data for the ValidSpliceMut SQL database and the associated Beacon application.
Development of the ValidSpliceMut database and Beacon
We created a publicly accessible Application Programming Interface (API) (https://beacon.cytognomix.com) that can be utilized to programmatically query variants passing filter thresholds described above (Dataset 1 21 ). It was built in accordance with the GA4GH Beacon v1.0.0 specification, which describes a Representational State Transfer (REST) API for genetic data sharing 22 . A Beacon accepts queries using an HTTP request and returns JavaScript Object Notation (JSON). Our Beacon implementation is coded in PHP 7.0 and utilizes a MySQL database TCGA-ACC TCGA-BLCA TCGA-BRCA TCGA-CESC TCGA-CHOL TCGA-COAD TCGA-DLBC   1,717  9,865  24,181  25,822  9,817  7,512  6,036   TCGA-ESCA TCGA-GBM TCGA-HNSC TCGA-KICH TCGA-KIRC  TCGA-KIRP TCGA-LAML   19,361  935  2,840  26,519  6,711  4,892  19,503   TCGA-LGG TCGA-LIHC TCGA-LUAD TCGA-LUSC TCGA-MESO TCGA-OV  TCGA-PAAD   1,346  12,461  18,262  2,628  303  88,136  1,585   TCGA-PCPG TCGA-PRAD TCGA-READ TCGA-SARC TCGA-SKCM TCGA-STAD TCGA-TGCT   90  944  3,083  20,024  12,515  20,245  467   TCGA-THCA TCGA-THYM TCGA-UCEC TCGA-UCS  TCGA-UVM  ICGC-CLLE ICGC- (version: 5.7.24) with indexes applied to variant ID, chromosome, and coordinate fields (GRCh37). The returned JSON object reports whether the variant was found within our Beacon dataset as well as metadata including splice site coordinate, splice type, site type, the IT-based measures R i,initial and R i,final , affected individual IDs, tumor type, Veridical evidence by type annotated with significance level, and, if known, the corresponding rsID with its average heterozygosity (dbSNP 150). The metadata for each variant sent to the Beacon Network is a concise subset of available results in our database. It includes the first relevant database entry, meaning that if the variant exists within multiple individuals only the first will contribute fields to the metadata. However, among this metadata is a hyperlink to our local website containing results for any remaining tumors.
We developed the website, ValidSpliceMut (Figure 1 ) to serve as a local interface to our Beacon, allowing users to manually search for a variant, by gene name or genome coordinate range. ValidSpliceMut automatically queries our Beacon, and formats the results of the search, if any. This website provides a complete view of variants, including Veridical-based evidence on all data related to every affected individual. If a variant is associated with multiple splice sites, the user is presented with a brief overview of all affected sites and must select a desired site to continue. To obtain the coordinate of the queried variant in gene-centric notation, a link is provided which queries the Mutalyzer API and generates coordinates for all available transcripts. ValidSpliceMut only reports transcripts for the gene affected by the variant.
A results page presents variant-specific data in tabular format and an expandable list of panels describing the affected individuals. Each of these panels contains Veridical output in tabular format for the selected tumor, a link to the tumor metadata at US National Cancer Institute (by querying the GDC API to obtain a UUID which is used to construct a link to the GDC data portal), an Integrative Genome Viewer (IGV) screenshot containing the variant (IGV screenshots are available for selected variants, see below), and a histogram which presents the expression levels of the variant-containing gene compared to all other gene expression levels across a selected normal tissue type (created dynamically using gnuplot 5.0). The tissue expression data is provided by GTEx (downloaded on 10/22/18). However, several tumor types did not have a GTEx equivalent (TCGA: CHOL, DLBC, MESO, READ, SARC, THYM and UVM; ICGC: MALY). The GNF Expression Atlas 2 23 was downloaded from the UCSC Genome Browser and was used for expression data for both lymph nodes (DLBC; MALY) and the thymus (THYM). For the remaining tissues, expression data from the following studies were obtained from the Genome Expression Omnibus (GEO): GSE76297 (CHOL), GSE2549 (MESO), GSE15781 (READ) GSE44426 (SARC), and GSE44295 (UVM).
To generate IGV images presented on the webpage, a bash script was written to automatically load the RNA-Seq BAM file of a patient with a mutation of interest into IGV, set the viewing window within the region of interest (300nt window, centered on the variant), sorted to bring reads containing the variant of interest to the top of the screen (to increase chance of visualizing mutant splice form), followed by a screen capture. The generation and storage of IGV images for all patient-mutation pairs would be prohibitive due to limitations in time and server space requirements. Therefore IGV images showing evidence of splicing abnormalities were generated only for patient-mutation pairs which met the most stringent criteria: the mutation was required to be flagged for junction-spanning cryptic site use, exon skipping, or intron inclusion (with mutation); the flagged category must include 5 or more reads in this category; if the variant is present in the dbSNP database (release 150), the frequency was required to be < 1% of the population; and the Veridical results, in which the mutations flagged were required to exhibit p ≤ 0.01 for at least one form of evidence of a splicing abnormality. In some cases, the splicing event observed by Veridical may not be present within the image window as the automated procedure used to create these images does not present all evidential sequence reads due to limitations on the number of reads that are shown. Additionally, reads appearing as exon skipping may instead indicate a pre-existing cryptic site outside of the viewing window (for examples, see 
Dataset validation and discussion
We have derived a GA4GH-standardized searchable resource for a large set of validated mRNA splicing mutations present in diverse tumor types. All variants passing QC in TCGA and ICGC cancer patients were analyzed with the Shannon pipeline 19 . This revealed that 1,094,749 variants were predicted to have significant impacts on normal mRNA splicing (380,852 natural and 752,472 cryptic splice sites; 38,575 affecting both types). Subsequent RNA-Seq analysis with Veridical 4 provided evidence of abnormal gene expression specifically associated with a subset of these variant(s), identifying 341,486 unique mutations.
Our results contrast with an earlier TCGA study that investigated alternative mRNA splicing 24 and demonstrated a limited set of non-constitutive exon-exon junctions attributable to cis-acting splicing mutations (n = 32). The 3,311 novel or rare variants from TCGA patients that we report specifically activate abnormal cryptic splicing (significant 'junction-spanning cryptic site use' reads found by Veridical). This exceeds the number reported in cited study that analyzed all available TCGA tumor transcriptomes (n=1,914) 25 . When ICGC datasets were included, a total of 3,650 variants were found to activate cryptic splicing. Comparing the validated cryptic splicing mutations we found with this previous report 25 , 1,176 variants fulfilled our IT-based filtering criteria for constitutive splicing mutations. Veridical validated mRNA splicing effects for 824 of these variants (70.1%). The remaining 738 variants were reanalyzed for changes within the binding sites of regulatory splicing factors (SRF) that might affect normal mRNA processing. Together, including the effects on constitutive splicing, IT analysis of SRFs 6 (SRSF1, SRSF2, SRSF5, SRSF6, hnRNPA1, ELAVL1, PTB and TIA1) cumulatively identified changes in binding strength in 1746 (91.2%) sites affected by these variants. A natural donor site is weakened, leading to a significant increase in ATM exon 57 (NM_000051.3) skipping events. Some reads with mutation depict wildtype, leaky splicing.
The mutation strengthens a cryptic site within BARD1 exon 4 (NM_000465.2). Reads which use this activated cryptic site contain the mutation (one exception). Some reads with mutation depict wildtype, leaky splicing. The mutation abolishes the natural acceptor of GATA3 exon 6 (NM_002051.2). This both increases the use of a pre-existing exonic cryptic splice site (4.2 > 5.6 bits; leads to an 8nt deletion) and significantly increases overall intron inclusion. 
COAD
This mutation weakens the natural acceptor of SMAD3 exon 9 (NM_005902.3) and predicts a cryptic site that does not appear to be used. A significant number of intron inclusion reads are observed. A distant pre-existing cryptic acceptor (9.6 bits; 3598nt from natural acceptor) was used in multiple reads. The natural acceptor of FAT1 exon 22 (NM_005245.3) is abolished, resulting in both intron inclusion (overall intron inclusion and the use of a 2.3 bit cryptic site 82nt upstream of natural acceptor) and use of two exonic cryptic sites (237nt and 234nt from the natural acceptor; R i =1.0 bits and -0.2 bits, respectively). 
KIRC
This mutation both significantly weakens the natural acceptor of SETD2 exon 18 (NM_014159.6) while strengthening a 4nt exonic cryptic site, which is used. 4.9 >-13.7 (Natural Site) LUAD
The natural donor of RB1 exon 18 (NM_000321.2) is abolished, leading to a significant increase in both exon skipping and intron inclusion. All intron inclusion reads contain the mutation of interest. Predicted splicing mutations present in multiple tumors from the same dataset that cause splicing abnormalities were analyzed to determine validation rates, since such variants were less subject to technical artifacts, such as sequencing errors. Violin plots indicate the distributions of the fraction of predicted and validated splicing mutations present in multiple patients relative to the total number of tumours carrying those mutations in the TCGA and ICGA datasets. To achieve statistical significance (95% C.I.), distributions of 1,379 validated variants shared by both datasets and present in at least 9 ICGC (left) and 24 TCGA (right) patients were compared. A higher overall proportion of mutations are validated in the ICGC dataset (average of 38.6% for ICGC and 27.8% for TCGA). The dashed lines in each plot indicate the median (middle line), the upper and lower quartiles of the mutation fractions.
Veridical validated splicing variants, which we define as mutations, were also tallied by tumor tissue type ( The ValidSpliceMut database consists of variants from both TCGA and ICGC, however the vast majority of variants were sourced from TCGA (329,758 of 341,597 flagged, unique variants were found only in TCGA patients; 96.5%). This had been expected, as the ICGC datasets were smaller (492 patients with available RNAseq data analyzed across 7 tumor types). There were 7,380 Veridical-flagged ICGC variants that were absent from TCGA patients; 4,459 variants were flagged in both TCGA and ICGC datasets (of which, 287 were not found in dbSNP 150). To evaluate the frequency of flagged TCGA and ICGC variants, we compared those shared between the two datasets that met SP criteria (n=9,485). We computed that for, a meaningful comparison (with 95% confidence interval [CI]), at least 9 ICGC and 24 TCGA patients should possess the shared mutation (typically, these correspond to common SNPs) and 1,379 shared variants met this criteria. We determined that on average, a higher average proportion of ICGC patients with shared mutations were flagged by Veridical compared to the TCGA cohort ( Figure 2 SKCM The mutation abolishes the natural donor of NRAS exon 2 (NM_002524.4), which promotes a significant increase in exon 2 skipping.
PPP6C
9:127933364C>T (c.171G>A) 6.7 > 3.7 (Natural Site) SKCM
The mutation weakens PPP6C exon 2 (NM_002721.4) natural donor, leading to increased intron inclusion. All reads which cross the splice junction contain the mutation. An intronic cryptic site is also activated (110nt downstream; R i =6.4 bits). A pre-existing cryptic donor within BAP1 exon 4 (NM_004656.3) is strengthened, leading to a significant increase in its use. This mutation leads to a 27 nt deletion in the mutated exon 4 mRNA.
Example mutations which alter splicing in tumor-associated genes found in patients with these tumor types. Mutations are hyperlinked to their ValidSpliceMut Beacon page, which provides additional material such as IGV images of the RNASeq evidence for the regions of interest. GRCh37 coordinates are indicated (70.0% vs. 42.4%, respectively). We speculate that this may be related to differences in sequence coverage, since TCGA variants were identified from a mixture of whole genome (WGS) and exomes 16 , while ICGC variants were exclusively derived by WGS.
To assess the predictive accuracy of SP, we also analyzed an independent set of experimentally-validated splicing mutations that altered exon definition (1,050 variants), originally sourced from the Genome Aggregation Database; gnomAD 26 and validated with a high throughput, multiplexed splicing minigene reporter assay 27 . Significant changes in constitutive splice site and/or (≥ 3 bit) SRF binding site strengths were found with SP for 1017 of these 1050 mutations (96.9%). Based on changes at constitutive splice sites alone, 447 variants were flagged (435 weaken natural sites, and 14 strengthen cryptic sites exceeding that of the most proximate natural splice site of the same polarity).
In Table 2 , we highlight a representative subset of validated splicing mutations which were identified in known driver genes implicated in the COSMIC (Catalogue Of Somatic Mutations In Cancer) Cancer Gene Census catalog (CGC) 28 . In total, 543 'Tier 1' CGC genes exhibited at least one Veridical-flagged variant present in the ValidSpliceMut database. These mutations were associated with either increased exon skipping, intron inclusion, and/or cryptic site use. Mutations in Table 2 are hyperlinked to their corresponding ValidSpliceMut webpage, which provides additional information, including specific expression evidence for each of the tumors in the database that support predictions made by SP.
Many mutations generated multiple types of abnormal read evidence present in mis-spliced transcripts. Interestingly, a subset of TCGA mutations (n=33) produced evidence for every type of abnormal splicing reported by Veridical. Dataset 2 29 (see Data Availability) describes 11 representative mutations that simultaneously increase exon skipping, intron inclusion, and activate (or significantly increase use of) a strengthened cryptic site. In all but one instance, the mutation weakens the natural site, while simultaneously strengthening an adjacent cryptic site. The only exception involves the gene SAP30BP, where simultaneously occurring mutations in the same read (in linkage disequilibrium; separated by 4 nucleotides) independently cause two separate splicing changes: g.73702087G>A (c.661-1G>A; abolishes the natural acceptor of exon 10) and g.73702091G>A (c.664G>A; creates a weak cryptic acceptor site). The combined splicing impact of these variants is significant exon skipping, intron inclusion, and use of the activated cryptic site.
This resource presents a set of splicing abnormalities in which we have the highest confidence because expression validation is required. We anticipate that some correct predictions of the Shannon pipeline may have not been validated by Veridical due to the limitations of mRNA detection; for example, either low expression of the gene harboring the mutation or nonsense-mediated decay of the corresponding transcript could be consistent with the effects of a valid splicing mutation, but in the absence of a sufficient number of abnormal reads, the mutation could not be confirmed. Indeed, expression of genes in tumours with validated splicing mutations exhibited greater overall gene expression than in other variants that were not validated in the same gene. The overall difference in gene expression between these two variant groups was statistically significant for 69.3% of genes based on the Student's t-test (90% C.I.). Furthermore, overall gene expression in the group with Veridical-flagged variants exceeded the nonflagged group for nearly all other genes (99.7%). Differences between expression levels of Veridical-validated splicing mutations and other predicted mutations suggests the possibility that unverified SP predictions may arise from lack of or low levels of gene expression of the genes containing this subset of variants.
The original SP version that processed most of the TCGA data did not report regulatory splicing variants which influence exon definition. The Automated Splice Site and Exon Definition Analysis (ASSEDA) server 6 analyzes individual variants for regulatory and constitutive IT changes. Due to time constraints, it was not feasible to perform a reanalysis with the upgraded SP of the entire set of ~209 million unique variants present in the TCGA and ICGC datasets. However, the SP upgrade did verify improvements in detection of both constitutive and regulatory splicing mutations using the set of validated mutations reported in a recent study 27 . This version of SP (available through our MutationForecaster system) is capable of predicting mutations in splicing regulatory sequences at higher throughput than ASSEDA and, like ASSEDA, accounts for relative abundance of mRNA isoforms by exon definition.
The Validated Splicing Mutation resource should significantly contribute to reducing the number of outstanding VUS in tumor (and possibly some germline) genomes, and substantially increases the number of functional variants with previously unappreciated consequences to mRNA splicing, in particular, those which activate cryptic splice sites. In our earlier study 20 , a subset of the TCGA breast cancer patient data was evaluated with IT-based tools, identifying 988 mutations as significantly altering normal splicing by Veridical (19% of total mutations flagged by IT). This database greatly expands the size of the repository. Here, a higher ratio of rare or novel mutations have been validated by Veridical (31% of total mutations were flagged by IT). The higher yields seen here could be related to mutations present in multiple samples from the same tumor type and other tumor tissues, which would be expected to increase the probability of observing abnormally expressed splice forms for the same mutation. 
Consent
Controlled-access TCGA and ICGC sequence data was approved by NCBI at the US National Institutes of Health (dbGaP Project #988: "Predicting common genetic variants that alter the splicing of human gene transcripts"; Approval Number #13930-11; PI: PK Rogan) and by the International Cancer Genome Consortium (ICGC Project #DACO-1056047; "Validation of mutations that alter gene expression"). 
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The manuscript by the Rogan group potentially provides an interesting resource. I would like to suggest to make it more accessible for the user, because in its current form it is very difficult to judge how reliable and strong the splicing predictions and RNAseq data in reality are. Our lab has checked some variants that are know to affect splicing, and it is very difficult to judge how this resource rates these. For example, Ri before and after mutation are difficult to interpret, it is unclear from this manuscript what these values in practice mean. The text in figure 1 that describes the reads under individuals (bottom of A) does not always correspond to the IGV screenhot in B. It is also unclear what figure C actually shows. The term anti-cryptic has not been defined. It is also not clear to me to what extent the predictions were confirmed for the entire set and whether certain types of predictions were more accurate than others. The resource may be very valuable, I would recommend to make it more accessible and understandable for the biological and diagnostic researcher, who could greatly benefit from it. 
Is the rationale for creating the dataset(s) clearly described? Partly
Are the protocols appropriate and is the work technically sound? Partly
Are sufficient details of methods and materials provided to allow replication by others? Partly
Emanuele Buratti
International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy I approve the amendments from Version 1.
Is the rationale for creating the dataset(s) clearly described? Partly
Are the protocols appropriate and is the work technically sound? Partly
Are sufficient details of methods and materials provided to allow replication by others? Partly
Are the datasets clearly presented in a useable and accessible format? Partly
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Reviewer Expertise: I have more than twenty years experience in the investigation of pre-mRNA splicing processes and especially their potential connection with a variety of human diseases, both monogenic (Cystic Fibrosis, Pompe Disease, Neurofibromatosis) and polygenic (Amyotrophic Lateral Sclerosis, Frontotemporal Dementia). I am the author of more than 160 research papers in peer-reviewed publications and of several articles in scientific books on these subjects (orcid.org/0000-0002-1356-9074) I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. 
Francesca D. Ciccarelli
Cancer Systems Biology Laboratory, Francis Crick Institute, London, UK The paper entitled "Pan-cancer repository of validated natural and cryptic mRNA splicing mutations" by Shirley, Mucaki and Rogan describes an extensive analysis of pancancer somatic variants in samples of the TCGA dataset to identify mutations that affect splicing. To this aim, the authors combine the methods that they previously developed to predict mutations affecting splicing, with a validation of their effect on matched mRNA data from TCGA.
The study is technically sound and follows a line of investigation that has been a long standing interest of the authors. Despite this, I have a number of comments that hopefully will help strengthen the study:
The authors write that their IT-based framework to predict slicing variants "has been validated in multiple studies" and they refer to numerous papers. However, in all of them they act as co-authors, showing that their method is mostly used by themselves and their collaborators. This is not necessarily a problem, but it would certainly strengthen the study if the authors would perform a comparative assessment of their performance with other available methods to predict splicing mutations, for example those in dbNSFP. This will provide a less biased interpretation of the final results. Somehow related to the previous point, the authors mention that their results "contrast with another TCGA study that investigated alternative mRNA splicing". In my opinion this point should be further explored: what are the main differences and what is the extent of overlap in concordant predictions? What are the possible reasons for these differences? This is important because the cited paper in Cancer Cell analysed the same dataset of mutations.
The authors notice that the number of variants which activate cryptic splicing exceed the number reported in a recently published study in Cell Reports. Similarly to before: what is the extent of overlap between the two datasets? Stating that a dataset is bigger than another one is not necessarily an indication that it is better. The authors validate ~27% of predicted splicing variants using the mRNA data (351k validated of the 1.2M predicted). This is a surprisingly low fraction. Later in the manuscript, the authors briefly discuss about the possible reasons of such a discrepancy. One of them is the possible occurrence of nonsense mediate decay which will not confirm the mutations because no or very few reads will be detected. However, as the authors acknowledge, the absence of supporting reads only in mutated individuals as compared to the presence of reads in WT sample would be a strong indication of the effective role of these mutations on splicing. This can be quantified from the same RNAseq data and in my opinion should be done. In general, the authors seem to exclude that their prediction method could lead to false positives. Rather they justify the poor overlap with limitations of mRNA detection. If this is the case, this should be quantified and probably a comparison with other prediction methods could help. Of the >351k mutations with an effect on splicing supported by RNA data, only 35 affect CGC genes. Is this only a subset of mutations affecting driver genes or is it the complete list? In the former case, I would suggest that the authors provide the full list as supplementary data. In the latter case, the authors should discuss the implication of such a low number. Considering that 6.
latter case, the authors should discuss the implication of such a low number. Considering that there are >700 CGC genes, does it mean that aberrant slicing is very rarely a driver event? Is the overwhelming majority of splicing variants passenger?
Is the rationale for creating the dataset(s) clearly described? Yes We thank the reviewer for their valuable comments. Our responses follow:
1. The authors write that their IT-based framework to predict slicing variants "has been validated in multiple studies" and they refer to numerous papers. However, in all of them they act as co-authors, showing that their method is mostly used by themselves and their collaborators. This is not necessarily a problem, but it would certainly strengthen the study if the authors would perform a comparative assessment of their performance with other available methods to predict splicing mutations, for example those in dbNSFP. This will provide a less biased interpretation of the final results.
Response: We have previously compared our mutation prediction methods with others. Mucaki et Hum. Mut. 34:556-65 (2013) showed that IT-based single mutation and exon definition methods al. performed as well or better than MaxEntScan and Human Splice Finder websites. MaxEntScan computes relative entropy which is similar to IT, except it applies a correction for local base composition (which does not measure free energy, in contrast with IT: J. Theor. Biol. 201:87-92, 1989). Human Splice Finder does not measure changes in binding affinity and its basis is . ad hoc We also reviewed all articles (300+) which have used IT-based tools to predict changes in splicing (Caminsky ., F1000Research 3:282, 2014). This reference covers the vast majority of studies et al that used IT-based bioinformatic tools for mutation analysis and, compared results obtained using these tools with other available software. The cited studies included a large proportion of mutations that we, ourselves, did not coauthor, or were analyzed by others, removing an obvious source of bias.
bias.
Regarding potential bias in our results, the IT-based position weight matrices (iPWMs) of splice recognition sites that we derived and use are based on a comprehensive set of splice sites spanning all known coding genes (see appendix of Rogan Pharmacogenetics & Genomics et al. 13(4):207-18, 2003). Other bioinformatic methods for splice site detection are based on many fewer splice sites for PWMs and are much more likely to be subject to bias based on how those sites were chosen. Also, the determination of information content in natural and mutated splice sites obeys the second law of thermodynamics (Schneider, J. Theor. Biol. 189:427-41, 1997); information contents have been formally proven to be related to binding affinities of splice site to splicesomes and splicing factors. MaxEntScan differs from IT because it applies a correction for local base composition, which is energetically and biochemically irrelevant to binding site affinity, and is therefore, biased.
As comparisons of IT with other methods have been covered previously, and the F1000Research Data Note article format is intended to specifically present results using the new resource we describe, in our opinion, reevaluation of other algorithms would not add anything of value to this manuscript.
2. Somehow related to the previous point, the authors mention that their results "contrast with another TCGA study that investigated alternative mRNA splicing". In my opinion this point should be further explored: what are the main differences and what is the extent of overlap in concordant predictions? What are the possible reasons for these differences? This is important because the cited paper in Cancer Cell analysed the same dataset of mutations.
Response: The paper being referred to in the reviewer's comment is Kahles , Cancer Cell., et al. 34(2):211-224.e62018. This paper reports: "In a joint analysis of and associations with cis trans 50% prior on each type, we identified 32 -and seven -sQTL (Bonferroni corrected p < cis trans 0.05)." Information regarding these cis-sQTLs can be found here:
. https://api.gdc.cancer.gov/data/3920a044-6874-4049-8010-55f0922243b7
However, the document that provided does not indicate that these are actual splicing mutations. The document contains SNP coordinates, but not sequence changes. An assessment of known rsIDs at these coordinates only accounted for only 7 of the variants in our database. In fact, none of the substitutions (nor the rsIDs) in the article could be related back to changes in mRNA splice strength. It is not possible to comparison the results presented in this paper to those in Kahles . et al (2018).
3. The authors notice that the number of variants which activate cryptic splicing exceed the number reported in a recently published study in Cell Reports. Similarly to before: what is the extent of overlap between the two datasets? Stating that a dataset is bigger than another one is not necessarily an indication that it is better. Table S1 ; "Passed Manual Review" tab) was sufficient to perform a comparison with our results. We scanned their manually reviewed variants using the Shannon Pipeline (SP). Despite reporting 1964 manually reviewed mutations, 50 mutations are shared between multiple patients (there are 1914 unique mutations total). 1510 of these mutations were found to alter at least one mRNA splice site (natural or cryptic), of which 1176 met our SP filtering criteria (either decreased natural site strength or cryptic splice sites strengthened by ≥2 bits and exceeding the strength of the nearest natural site of the same polarity).
We considered the possibility that splicing mutations in Jayasinghe that were not flagged by et al. SP could have instead altered the strength of splicing regulatory factor binding sites (SRFs). The high-throughput IT-based variant analysis tools needed to address this question were not available at the time the TCGA genomic data were processed. We recently introduced a new version of SP which is capable of analyzing variants impacting both constitutive splice sites and SRFs (including SRSF1, SRSF2, SRSF5, SRSF6, hnRNPA1, ELAVL1, PTB and TIA1). Upon analysis of the variants in Jayasinghe for IT-derived changes in natural, cryptic and SRF binding site et al. strengths, 1746 of the 1914 (91.2%) were found to be significant. It is conceivable that remaining unclassified variants may affect binding by splicing factors for which we have not yet derived iPWMs (i.e. SRSF7).
Of the 1176 variants meeting our filtering criteria, 824 were flagged by Veridical (70.1%). Interestingly, 27 Veridical-flagged mutations alter the same genomic coordinate in different tumours and another 64 affect the adjacent genomic coordinate within the same splice site in other individuals. We further investigated the remaining mutations (those evaluated, but not flagged) to better understand the discrepancy. In approximately 10% of cases, Veridical did not find any alternative validating cryptic splicing events in the region that contrasted with the read distribution in the set of control transcriptomes. For example, chr9:35389842G>C in TCGA-CN-5370 was expected to abolish the natural acceptor site of exon 24, however the read counts for UNC13B intron inclusion in the RNAseq data were too sparse to be deemed significant (p=0.33).
Jayasinghe also found mutations in TCGA patients that were not evaluated in our study. This et al. could occur for either because the RNASeq BAM file for a particular TCGA patient failed to download, or the "key" file that associates the BAM file to its TCGA name was incomplete in some tumors (i.e. TCGA-CG-4436; TCGA-STAD), due to both the BAM file name and header lacking this information. This would not impact the accuracy of the data that is present in our database or that we report, only the level of concordance between our results and those of Jayasinghe . et al When comparing this dataset with our own, we discovered an instance where discrepant RNAseq data for the same tumour in the same TCGA patient led to different IT results. Originally, Veridical did not find a significant splicing change in exon 14 at the +1 position, a G>A mutation POLR1B g.113331138G>A, present in patient TCGA-Z6-AAPN in the ESCA dataset. When we manually reviewed the RNAseq BAM file used in this analysis, alternate or exon skipped splice forms were not observed, confirming the results reported from Veridical. In fact, TCGA deposited two separate BAM files containing RNAseq data for this same patient: "TCGA-Z6-AAPN-01A-11R-A406-31_rnaseq.bam" and "UNCID_2681450.b17c4505-8a84-4cdd-8782-fbc456deb2a6.sorted_genome_alignments.bam". The latter BAM file shows evidence of both predicted exon skipping and activation of a cryptic acceptor site 12 nt downstream of exon 14 of . Comparison of SNPs between these BAM POLR1B files in other genes did not show any evidence of sample switching or contamination. Although this issue does not appear to be widespread in the TCGA dataset, such discrepancies exceed the scope of our study, and rightfully should be addressed by TCGA.
Nevertheless, this discovery did prompt us to re-analyze the TCGA-ESCA variants through Veridical using the second set of BAM files, and we have now included those results to Veridical using the second set of BAM files, and we have now included those results to ValidSpliceMut. In this new set, the previously mentioned mutation is deemed significant POLR1B due to increased exon skipping (86 reads showing exon skipping; p=0.0000).
4. The authors validate ~27% of predicted splicing variants using the mRNA data (351k validated of the 1.2M predicted). This is a surprisingly low fraction. Later in the manuscript, the authors briefly discuss about the possible reasons of such a discrepancy. One of them is the possible occurrence of nonsense mediate decay which will not confirm the mutations because no or very few reads will be detected. However, as the authors acknowledge, the absence of supporting reads only in mutated individuals as compared to the presence of reads in WT sample would be a strong indication of the effective role of these mutations on splicing. This can be quantified from the same RNAseq data and in my opinion should be done.
In the revision of this paper, the fraction of validated predicted splicing variants in the ValidSpliceMut database increased from 27% to 31%, as a result of a series of improvements in the software used for processing. SP was significantly upgraded over the course of this project,. The previous iteration would incorrectly report information changes at pre-existing splice sites adjacent to certain mutations. These sites were characterized by genomic coordinates that were altered by insertions or deletions (indel), regardless of whether the site overlapped or included the sequence change. In such instances, some altered natural splice sites could be designated as cryptic sites. SP also reported changes at cryptic acceptor and donor sites in the first and last exons of a gene, respectively, which were not likely to have a meaningful impact on splicing. Therefore, all datasets processed prior to this upgrade were reanalyzed for indel variants. The TCGA ESCA dataset was reprocessed with a second set of RNAseq BAM files (see above response to point 3), which increased the fraction of flagged mutations for that tumor type. Finally, we processed an additional 7 tumor datasets from ICGC and included the validated mutations in our primary beacon database. The statistics of mutations, their distributions and support have been updated in the present version of the manuscript.
From our perspective, the proportion of variants validated is not "a surprisingly low fraction". The results reported here are consistent with our previous published studies (Dorman , Sci. Rep. et al. 4: 7063, 2014) . Aside from NMD, as demonstrated below, some mutations that significantly alter splice site strength may not have been flagged by Veridical as a consequence of low levels of expression of the gene in the tumor (or controls) itself. Furthermore, Veridical cannot make an accurate assessment of the region of interest in control samples if these lack sufficient read abundance levels to determine the probability (p-value) of observing expression in the mutation-containing vs control samples. Also, our analysis did not take into account other impacts of the variant on sequences that influence exon definition, such as binding to splicing regulatory factors or mRNA secondary structure. In our response to point 3, we described a discrepancy in BAM file sources, which could also lead to a lower fraction of confirmed variants. Finally, miscalled variants (despite the stringent quality control criteria applied to select variants) could contribute to the fraction of variants not supported by Veridical analysis. Such technical artifacts have been shown to be quite common in exome sequencing in areas of the genome characterized by low mappability (from Shi , Cell Rep. 2018 Nov 6;25(6):1446-1457, 2018): "Examination of the et al. genomic locations of mutations revealed that 41.1% of the artifactual somatic mutations occurred in regions of low mappability compared with only 6.4% for the validated somatic heterogeneous mutations."
As indicated in our response to point 3, the previous version of this paper only evaluated variants for their impact on constitutional mRNA splice sites and cryptic sites, and excluded impacts of for their impact on constitutional mRNA splice sites and cryptic sites, and excluded impacts of mutations at splicing regulatory factor binding sites (SRFs). The scope and time required to assess SRFs precluded the reanalysis of all datasets for such changes. However, to address the issue raised by the reviewer, we evaluated the degree to which ignoring SRFs would affect the overall discovery of splicing-related variants. The updated version of the Shannon Pipeline (SP) with this capability was used to examine 1050 mRNA splicing variants that have been demonstrated to affect exon recognition (Cheung , Mol Cell. 2019 Jan 3;73(1):183-194.e8). These splicing et al. variants were experimentally validated using a high throughput, multiplexed splicing minigene reporter assay in that study. SP reported a change in splicing and/or SRF binding strength for 1017 of these 1050 mutations (96.9%; where change in SRF strength was ≥ 3 bits). After accounting for SRF location (e.g. exonic TIA1 sites were eliminated, since these have not been proven to have splicing effects; see Table 1 of Caminsky , F1000Res.;3:282, 2014, for a full description of et al. each SRF), the number of flagged variants was reduced to 940 (89.5%). Based on changes in constitutive splice site strength alone, 447 variants were flagged (435 weaken natural sites, 14 strengthen cryptic sites to a level exceeding the nearest natural site). Therefore, 46.3% of the constitutive mutations at natural or cryptic splice sites were also flagged by SP. This suggests that the lower predictive accuracy of SP in our original submission was, in part, due to the limitations in its ability to detect pathogenic mutations in SRF binding sites.
We addressed the reviewer's suggestion to compare expression of the same gene in tumours with Veridical-validated mutations with other tumors with SP-predicted mutations in the same gene that were not experimentally validated. To perform the analysis, we obtained pre-processed mRNA expression data from the same RNAseq sources of TCGA patients from cBioPortal ( ; provisional datasets were used, which contained largest number of patients www.cbioportal.com for each tumor type). We extracted these gene expression values with a software program we wrote that determined transcripts per million (TPM) for each gene containing a SP-flagged variant. Expression values for gene present multiple times (due to the presence of multiple splice isoforms) were averaged for the particular tissue from which they were derived.
We separated mRNA expression values for each gene in TCGA patients into the Veridical-flagged vs. non-validated SP-predicted mutation categories, and performed a Student's t-test on the two groups. The expression values of 58.2% of genes were statistically distinct with 90% confidence; >2 patients per category per gene). With at least 10 patients per category, the number of statistically different genes increased to 69.3%. Among these genes, patients with . These inherent Veridical-flagged variants had higher overall gene expression in 99.7% of cases differences in expression suggest that the failure to validate predicted mutations may be related to little or no expression of these genes in tumour and/or control samples, rather than to accuracy of IT prediction methods. Non-sense mediated decay could be responsible for the decreased expression of these mutated genes in the tumour genomes that carry them, or the failure to validate could be related to low levels of expression of these genes in the particular tissues from which the tumours were derived. This analysis is now described in the revised manuscript ('Dataset validation and discussion,' para. 8).
: The gene expression data from cBioPortal had some limitations: 4196 genes containing Note variants flagged by SP are not present in the mRNA expression datasets, though the vast majority occurred in non-coding RNAs (i.e. 145 microRNAs, 194 LINC RNAs) or other uncharacterized RNAs (e.g. 324 'LOC' RNAs). Furthermore, certain TCGA patients that we analyzed were not available in cBioPortal among the available expression datasets (2 TCGA-BRCA, 18 TCGA-COAD, 19 TCGA-GBM, 1 TCGA-HNSC, 1 TCGA-LUAD, 119 TCGA-OV, 4 TCGA-READ, 4 TCGA-STAD, 4 TCGA-THCA, and 7 TCGA-UCEC patients). Nevertheless, sufficient data were TCGA-STAD, 4 TCGA-THCA, and 7 TCGA-UCEC patients). Nevertheless, sufficient data were obtained for the analysis that we carried out.
Furthermore, this analysis has other caveats, especially regarding the accuracy of RNAseq quantification between samples, even upon normalization of the data. The vast majority of TCGA tumor samples do not have a matched normal counterpart, and many TCGA tumor datasets (e.g. TCGA-LAML) do not provide any normal control RNAseq data at all. While we could perform an analysis in which the tumor is compared to a set of normals for the same tissue, variation in expression between different individuals would obfuscate evidence of any apparent NMD caused by the mutation. A 50% reduction of expression (or less) may not be observable under these conditions. 5. In general, the authors seem to exclude that their prediction method could lead to false positives. Rather they justify the poor overlap with limitations of mRNA detection. If this is the case, this should be quantified and probably a comparison with other prediction methods could help. The performance of IT-based methods for predicting splicing mutations has been well established over the past two and a half decades. Re-evaluation of its accuracy is not necessary, and this issue is, at best, only tangentially relevant, to the purpose of presenting the resource described in a Data Note article.
6. Of the >351k mutations with an effect on splicing supported by RNA data, only 35 affect CGC genes. Is this only a subset of mutations affecting driver genes or is it the complete list? In the former case, I would suggest that the authors provide the full list as supplementary data. In the latter case, the authors should discuss the implication of such a low number. Considering that there are >700 CGC genes, does it mean that aberrant splicing is very rarely a driver event? Is the overwhelming majority of splicing variants passenger?
Response: There are 25 CGC genes indicated in Table 2 , however these were never intended to be interpreted to be a complete list of CGC genes with Veridical-flagged mutations. The table has been renamed to indicate that these are a set of representative mutations. In the previous version of this paper, the number of variants ("n=25") did not indicate the total number of CGC genes. This Reviewer Expertise: I have more than twenty years experience in the investigation of pre-mRNA splicing processes and especially their potential connection with a variety of human diseases, both monogenic (Cystic Fibrosis, Pompe Disease, Neurofibromatosis) and polygenic (Amyotrophic Lateral Sclerosis, Frontotemporal Dementia). I am the author of more than 160 research papers in peer-reviewed publications and of several articles in scientific books on these subjects (orcid.org/0000-0002-1356-9074) I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative Your article is indexed in PubMed after passing peer review Dedicated customer support at every stage For pre-submission enquiries, contact research@f1000.com
